ArticleFrontiers in immunology2026
Case Report: Upadacitinib and apremilast combination therapy for guselkumab-induced paradoxical eczema in psoriasis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is an immune-mediated inflammatory skin disease. Although biologics have markedly improved psoriasis symptoms, they may occasionally trigger paradoxical inflammatory reactions, particularly with IL-17A or TNF-α inhibitors. However, paradoxical inflammatory reactions associated with the IL-23 inhibitor guselkumab is exceptionally rare. We describe the case of a 70-year-old male with a 5-year history of psoriasis who had previously received tofacitinib for one year without achieving complete clearance. Following the initiation of guselkumab, the patient developed paradoxical eczema. Subsequent treatment with cyclosporine and the TYK2 inhibitor deucravacitinib proved ineffective. Ultimately, combination therapy with the JAK1 inhibitor upadacitinib and the PDE4 inhibitor apremilast achieved satisfactory control of both the paradoxical eczema and the underlying psoriatic lesions. This case highlights that upadacitinib used in combination with apremilast can effectively reverse paradoxical inflammatory reactions while sustaining psoriasis control. This dual-targeting strategy offers a novel therapeutic option for biologic-induced paradoxical reactions, and its broad-spectrum anti-inflammatory properties and potential synergistic effects warrant further clinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.